MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Alterations in the MET oncogene are observed in non-small-cell lung cancer (NSCLC).
• The survival benefit of MET inhibitors in NSCLC treatment remains a subject of debate.
• Existing therapies include epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and standard chemotherapy.

Purpose of the Study:

• To evaluate the survival benefit of combining MET inhibitors with EGFR-TKIs or chemotherapy in advanced or metastatic NSCLC.
• To analyze the impact of MET inhibitors on progression-free survival (PFS) and overall survival (OS).

Main Methods:

• A systematic computerized search of electronic databases was conducted.
• A meta-analysis included seven studies with a total of 2,577 patients.
• Hazard ratios (HR) and 95% confidence intervals (CI) were calculated to assess survival outcomes.

Main Results:

• Patients receiving an additional MET inhibitor showed no significant improvement in PFS (HR = 0.92 [95% CI: 0.79-1.08], P = 0.33) or OS (HR = 1.0 [95% CI: 0.90-1.11], P = 0.97) compared to placebo.
• In a subgroup analysis, patients with MET-high NSCLC demonstrated a trend towards longer survival with MET inhibitors (HR = 0.76 [95% CI: 0.58-1.01], P = 0.06).

Conclusions:

• The addition of MET inhibitors to EGFR-TKIs or chemotherapy does not provide a survival benefit over placebo in advanced or metastatic NSCLC.
• While MET-high tumors may benefit, further research into specific biomarkers is crucial for identifying ideal candidates for MET inhibitors in NSCLC.